The $25 million cash infusion will substantially strengthen ISCO's balance sheet, but the sale of LCT removes a revenue-generating business unit. Monitor the closing timeline and any post-closing adjustments that could affect net proceeds. Post-close, ISCO's remaining business and use of proceeds will determine the re-rating potential.
Price Chart
Executive Summary
International Stem Cell Corporation (ISCO) signed a definitive agreement to sell its wholly-owned subsidiary, Lifeline Cell Technology, LLC (LCT), to American Type Culture Collection, Inc. (ATCC) for $25 million in cash, subject to customary working capital and indebtedness adjustments. The transaction provides a significant cash infusion to ISCO and is expected to close in the third quarter of 2026, pending stockholder approval and customary conditions.
Key Financial Metrics
Key Facts
- Purchase price of $25 million (all cash) for 100% of LCT membership interests
- Closing expected in Q3 2026, subject to stockholder approval and customary conditions
- Requisite holders (>50% voting power) have executed support agreements to vote in favor of the transaction
- Indemnity escrow of $2.5 million and adjustment escrow of $100,000 established
- Five-year non-compete and non-solicitation restrictions on ISCO post-closing
- Transition services agreement entered into concurrently with the purchase agreement
Financial Impact
Cash consideration of $25 million, plus potential net working capital and cash adjustments, less indebtedness and escrow amounts
Risk Factors
- Failure to obtain stockholder approval or regulatory clearance could scuttle the deal
- Post-closing working capital adjustments could reduce the net cash received
- Loss of LCT's revenue stream may materially shrink ISCO's top line
- Execution risk in transitioning operations and retaining key employees
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-005555 |
| Document: intlstemcell_ex1001.htm | 0001683168-26-005555 |
| Document: intlstemcell_8k.htm | 0001683168-26-005555 |
| Document: 0001683168-26-005555-index-headers.html | 0001683168-26-005555 |
| Document: 0001683168-26-005555-index.html | 0001683168-26-005555 |
| Document: 0001683168-26-005555.txt | 0001683168-26-005555 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 6w ago | 144 | $0.3600 | awaiting T+60 | — | $0.1500 (−58.33%) |
Sep 8, 2026 7w ago | 8-K | $0.3700 | awaiting T+60 | — | $0.1500 (−59.46%) |
Jul 15, 2026 14w ago | 8-K | $0.2100 $0.2800 | ▲ +33.33% | ▲ +29.37% | $0.1500 (−28.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers